Option chain shows key data for Tonix Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tonix Pharmaceuticals.

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock, Option Chain

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Keep An Eye On Earnings Reports

News

Movers

TNXP

Tonix shares are moving higher on Friday after the company provided preliminary 2024 fiscal-year financial results.

What&#39;s Going On With Tonix Pharmaceuticals Shares Friday?

Palantir,Technologies,Japan,Logo,,Tokyo,,Japan,2024,Sep.15

Pre-Market Outlook

Markets

Trading Ideas

AREB

AZTR

BCTX

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

PLTR

REBN

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

Eurozone

Commodities

Intraday Update

GHRS

NSSC

Crude Oil Moves Higher; Owens &amp; Minor Shares Plummet

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

Press Releases

Stocks to Watch Under $1: MSS, KWE, PRSO, PNPN.V, TNXP, KAVL for December 2024

Health Care

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

"Breakthrough Stocks to Watch: WATT, STEM, PNPN.V, NXU, REKR Powering Santa Rally Momentum, more inside!"

Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

Management

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

INTZ

KAVL

PNPNF

PRSO

REKR

STEM

TSXV:PNPN

WATT

AlloVir

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

FibroBiologics

FibroGen

ImmuCell

Immix Biopharma

Kala Bio

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lantern Pharma

MAIA Biotechnology

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

Spero Therapeutics

Xilio Therapeutics

Alliance Global Partners

Dawson James

Noble Capital Markets

Untitled design - 2024-12-07T011441.837

Biotech

General

Tonix&#39;s TNX 102-SL Could Offer New Hope Of Pain Relief Without Narcotics For Fibromyalgia Sufferers

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

BVNKF

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Screenshot 2024-08-01 at 5.06.20 PM

FDA Recognizes Fibromyalgia As A &#39;Serious Condition&#39; And Fast-Tracks New Drug Candidate

Screenshot 2024-07-23 at 10.19.53 PM

Beyond &#34;One Bug, One Drug&#34; – Tonix Pharmaceuticals Secures Up To $34 Million In Funding From U.S. Department Of Defense To Develop Broad-Spectrum Antiviral

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Comments

Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga